nevity Secures $20M to Pioneer Cell Reprogramming for Metabolic Disease
December 15, 2025, 9:38 pm
Junevity, a San Francisco biotech firm, just raised $20 million in seed funding. This investment fuels development of its lead drug, JUN_01. JUN_01 targets type 2 diabetes and obesity using a novel siRNA approach. The company’s RESET platform identifies key targets for cell reprogramming. Early data shows significant metabolic improvements with infrequent dosing. This funding positions Junevity for clinical trials in 2026. The company aims to expand beyond metabolic diseases into neurodegeneration. This represents a significant advance in cell reprogramming therapeutics.
---
Junevity is changing the game. The biotech company secured $20 million in seed funding. This follows a recent $10 million injection. Goldcrest Capital and Godfrey Capital led both rounds. The money will accelerate clinical development.
Junevity focuses on cell reprogramming. They use silencing RNA (siRNA) technology. Their lead program, JUN_01, targets type 2 diabetes and obesity. It’s a first-of-its-kind therapeutic. It reprograms metabolism with siRNA.
Preclinical results are promising. JUN_01 reduced blood glucose levels. Insulin sensitivity improved. Weight loss was robust. Lean mass was maintained. Weight regain was resisted. Dosing is infrequent – every six months. This is a major advantage.
The company’s RESET platform is key. It combines multiple data sources. Human disease omics are analyzed. Genetic linkages are mapped. Machine learning and AI are utilized. This identifies novel targets. These targets are previously “undruggable” transcription factors.
JUN_01 targets a specific transcription factor. This factor regulates metabolic dysfunction. It impacts insulin signaling and appetite. The science stems from research at UCSF. Dr. Janine Sengstack’s work showed cellular state reset. Repressing a single factor can achieve this.
Junevity was founded in 2023. John Hoekman is the CEO and co-founder. He previously co-founded Impel Pharmaceuticals. The company is expanding its pipeline. Neurodegeneration is a new focus. They aim to apply reprogramming to major tissues. This includes those involved in chronic diseases.
This funding is critical. It allows Junevity to begin clinical trials. Initial studies are planned for the second half of 2026. The company is validating its siRNA approach. This could revolutionize treatment for metabolic diseases. It offers a potential alternative to current therapies. It could also complement existing treatments like GLP-1s.
The long-term vision is ambitious. Junevity wants to reprogram cells across the body. This could address a wide range of complex diseases. The RESET platform is designed for scalability. It can identify targets for various conditions.
This is more than just a funding round. It’s a step towards a new era of medicine. Cell reprogramming offers a powerful approach. It addresses the root causes of disease. Junevity is at the forefront of this innovation. The company’s progress will be closely watched. Investors see significant potential. The future of metabolic disease treatment may be here.
**Keywords:** Junevity, siRNA, cell reprogramming, type 2 diabetes, obesity, metabolic disease, biotechnology, funding, Goldcrest Capital, Godfrey Capital, RESET platform, clinical trials, IND-enabling, UCSF, John Hoekman, transcription factors, metabolic dysfunction, insulin sensitivity, weight loss.
---
Junevity is changing the game. The biotech company secured $20 million in seed funding. This follows a recent $10 million injection. Goldcrest Capital and Godfrey Capital led both rounds. The money will accelerate clinical development.
Junevity focuses on cell reprogramming. They use silencing RNA (siRNA) technology. Their lead program, JUN_01, targets type 2 diabetes and obesity. It’s a first-of-its-kind therapeutic. It reprograms metabolism with siRNA.
Preclinical results are promising. JUN_01 reduced blood glucose levels. Insulin sensitivity improved. Weight loss was robust. Lean mass was maintained. Weight regain was resisted. Dosing is infrequent – every six months. This is a major advantage.
The company’s RESET platform is key. It combines multiple data sources. Human disease omics are analyzed. Genetic linkages are mapped. Machine learning and AI are utilized. This identifies novel targets. These targets are previously “undruggable” transcription factors.
JUN_01 targets a specific transcription factor. This factor regulates metabolic dysfunction. It impacts insulin signaling and appetite. The science stems from research at UCSF. Dr. Janine Sengstack’s work showed cellular state reset. Repressing a single factor can achieve this.
Junevity was founded in 2023. John Hoekman is the CEO and co-founder. He previously co-founded Impel Pharmaceuticals. The company is expanding its pipeline. Neurodegeneration is a new focus. They aim to apply reprogramming to major tissues. This includes those involved in chronic diseases.
This funding is critical. It allows Junevity to begin clinical trials. Initial studies are planned for the second half of 2026. The company is validating its siRNA approach. This could revolutionize treatment for metabolic diseases. It offers a potential alternative to current therapies. It could also complement existing treatments like GLP-1s.
The long-term vision is ambitious. Junevity wants to reprogram cells across the body. This could address a wide range of complex diseases. The RESET platform is designed for scalability. It can identify targets for various conditions.
This is more than just a funding round. It’s a step towards a new era of medicine. Cell reprogramming offers a powerful approach. It addresses the root causes of disease. Junevity is at the forefront of this innovation. The company’s progress will be closely watched. Investors see significant potential. The future of metabolic disease treatment may be here.
**Keywords:** Junevity, siRNA, cell reprogramming, type 2 diabetes, obesity, metabolic disease, biotechnology, funding, Goldcrest Capital, Godfrey Capital, RESET platform, clinical trials, IND-enabling, UCSF, John Hoekman, transcription factors, metabolic dysfunction, insulin sensitivity, weight loss.